txa2r

CGS 15435 is a potent thromboxen (TxA2) synthetase inhibitor (IC50: 1 nM). CGS 15435 acts on PGI2 synthase, cyclooxygenase and liposynthase with much less selectivity than on thromboxin synthase.

Furegrelate sodium (U-63557A) is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium(U-63557A) inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.

FUREGRELATE, a thromboxane A2 (TxA2) synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.

LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.

Daltroban (SKF 96148) is a specific thromboxane A2 (TXA2) receptor antagonist. Daltroban shows protective effect in reperfusion injury. Daltroban increase intracellular calcium in vascular smooth muscle cells.

Linotroban(CL-871502) is a potent selective thromboxane (TXA2) receptor antagonist with antithrombotic activity.

Dazmegrel (UK 38,485) is a potent and specific thromboxane A2 (TXA2) synthase inhibitor for the prevention of increased whole platelet aggregation in normal pregnancy.

Sulotroban potassium is a small molecule thromboxane A2 receptor (TXA2R) antagonist that can be used to study myocardial infarction and thrombosis.

Triflusal (UR1501) is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.

NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)

U-46619 is an effective thromboxane A2 (TXA2) agonist and a thromboxane A2 analog (endoperoxide), capable of inducing contraction in the aortic smooth muscle (SM) of mice with a myosin light chain 9 (Myl9) gene deletion.

(R)-(+)-Bay-K-8644 is a Ca2+ channel and dihydropyridine agonist that inhibits Ba2+ currents (IBa), induces central respiratory depression in cats, and inhibits platelet activation through competitive antagonism of thromboxane A2-prostaglandin H2 receptors.

sulotroban is a TXA2 receptor antagonist that acts synergistically with iloprost to inhibit TXA2-dependent platelet activation.

Ramatroban (BAY u3405) (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.

Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

RS-601 is a potent dual leukotriene D4/thromboxane A2 inhibitor that inhibits antigen-induced airway hyperresponsiveness (AHR) and shows asthmatic effects in a guinea pig model of asthma.

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

YM158 free base is a potent and selective antagonist of the TXA2 and LTD4 receptors (pA2 values of approximately 8.81 and 8.87).

KP496 is a selective, dual antagonist for the Thromboxane A2 receptor (TP) and the Leukotriene D4 receptor (cysLT1).

BM 567 (compound 1) is a thromboxane A2 receptor (TXR) antagonist and thromboxane A2 synthase (TXS) inhibitor with anti-thrombotic effects, exhibiting IC₅₀ values of 1.1 and 12 nM respectively.

8-iso Prostaglandin F1α is an isoprostaglandin produced from arachidonic acid that induces concentration-dependent vasoconstrictor effects in pulmonary arteries (PA), pulmonary veins (PV) and mesenteric arteries (MA) through activation of TXA2R, tyrosine kinases and Rho kinases.

8-iso Prostaglandin F1β, an isoprostane produced from arachidonic acid, induces concentration-dependent vasoconstrictor effects in pulmonary arteries (PA), pulmonary veins (PV) and mesenteric arteries (MA) through the activation ofTXA2R, tyrosine kinase and Rho kinase.

BM-531 is a thromboxane A2 receptor (TXA2R) antagonist (IC₅₀ = 7.8 nM) and thromboxane synthase inhibitor exhibiting antiplatelet activity. It inhibits arachidonic acid-induced platelet aggregation and suppresses the second wave of ADP-induced aggregation.